ICBII Update on the Road to the Cure (February, 2022)Category: Road to the Cure
A Unique Approach to Overcome the Deficiencies of Prior Scientific Art
Patients may be wondering why there is NO CURE for Parkinson’s disease despite multi-billions of dollars dedicated to finding a cure by well-known foundations, academics, and pharmaceutical companies during the last 30 years.
To put it simply, in the first place, the world scientific community still does not know what the real Parkinson’s disease trigger is. Secondarily, disease diagnosis takes place too late to reverse neuronal damage. Thirdly, biased and perhaps political research grants awards. Based upon the personal experience of Dr. Ram Bhatt, who was on the NIH Grant Review Board, reviewers of grants favor grants from their friends rather than non-friends regardless of the grants’ merit. Fourth, government organizations such as NIH and private foundations, such as Michael J Fox Foundation and Alzheimer’s Foundation, have been giving research grants to investigators based upon their affiliations and not what they accomplished with the prior grants. Fifth, pharmaceutical companies for decades have been insisting that they can obtain different and perhaps improved results by adhering to the same way of doing things (technology) again and again. While all these investigators make their livelihood from grants obtained from either tax payors’ money or donations to foundations, patients and their loved ones are the real victims. The patient’s hopes have been high to hear some positive news from social media only to find later it was nothing but another false hope. The biggest cruel hoax of the 21st century has been the FDA’s recent approval of Biogen’s Aduhelm with no demonstrated benefits to Alzheimer’s patients.
In addition to early diagnosis and understanding the real trigger of Parkinson’s, it is equally important that the potential curative and disease-modifying therapeutic drug goes across the blood-brain barrier (BBB) into the central nervous system (CNS) in therapeutically adequate doses. For decades, most pharma scientists have been using mouse monoclonal-based therapies for neurodegenerative diseases despite the very poor (0.1%) brain uptake of such antibodies. At such a low brain uptake, it is mind-boggling that such antibodies have been used to cure neurological disorders for decades.
Hope - Basic research scientists all over the globe deserve a special Kudo for trying to understand what the real trigger of neurodegenerative diseases is. While the underlying pathophysiology of Parkinson’s is complex, it appears that a mitochondrial dysfunction is an early event that has an established and prominent role in Parkinson’s and most other brain disorders. Mitochondria is the “powerhouse” of neurons and all cells in our body. Its fundamental role is to produce the energy needed by cells and neurons. In addition, mitochondria are the epicenter of many metabolic pathways such as calcium homeostasis, signaling and regulation of cell death, lipid synthesis, reactive oxygen species production, and cellular control. It turns out that the oligomeric alpha-synuclein, a form long before fibrillation and Lewy body formation, along with other proteins damage mitochondria, which initiates a cascade of other processes such as demyelination of axons that lead to neuronal death in the substantia nigra of patients.
ICB International, Inc., (“ICBII”) has a Unique Approach to Overcoming the Deficiencies of Prior Scientific Art.
1) We have developed technology for the early diagnosis of neurodegenerative diseases. This technology has been shown to detect and quantify the level of pathogenic protein in the brain of Parkinson’s mice. The company is actively looking for funding to translate this technology from mice to humans. Our long-term goal is to introduce the screening of CNS diseases at an early age of about 30 to 40 years like the screening of colon cancer beginning at the age of about 50 years. Early detection will be the key to eradicating CNS diseases.
2) Repair Mitochondria and axon damage by deactivating genes and proteins that thwart mitochondria and axon regeneration. The Company is actively talking to investors to fund this new approach.
Donors, and investors with the wherewithal are encouraged to look outside of the box and perhaps consider not pouring their donations into organizations that have not produced a cure for Parkinson’s after spending billions in US dollars. If they haven’t produced a cure in the last 2 to 3 decades, chances are dismal they can do so with additional donations.
WOULD YOU LIKE TO HELP get ICBII’s drugs to market faster? The joy of being a part of this historical event can be had by helping ICBI find the funds to bring these trials to fruition through your investing, and by finding others with the financial ability and humanitarian mindset to accomplish the, until now, impossible. Please contact ICBI directly through their website ICBII.com or by phone 858-455-9880, or contact Jo Rosen at PRO for a personal introduction to the scientists.
IMAGINE the world without Parkinson’s, MSA, or Alzheimer’s disease.